NCT Number: NCT04954378
Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer
Retrospectively analyzed radiomics features of pancreatic ductal adenocarcinoma to predict staging and prognosis
Looking for future studies?
Notify MeKey information
About this study
Pancreatic cancer is the most malignant tumor of the digestive system and the seventh leading cause of cancer-related death worldwide.The rate of lymph node metastasis in pancreatic cancer is as high as 59%.Lymph node metastasis is an important prognostic factor, which is closely associated with poor prognosis of pancreatic cancer patients.Preoperative accurate prediction of lymph node status has important clinical value.At present, the preoperative LN status of pancreatic cancer patients is mainly evaluated by conventional imaging methods such as CT and MRI.The accuracy of evaluating LN state only from the perspective of morphology is poor.Ductal adenocarcinoma of the pancreas is highly malignant, has a median disease-free survival of only about 1 year, and most pancreatic cancer patients eventually relapse.At present, TNM staging system is mainly used for prognosis evaluation.However, even among patients with the same TNM stage, the prognosis is still significantly different, which reflects the lack of prognostic information provided by the TNM stage.Imaging omics extracts a large number of quantitative features from medical images in a high-throughput manner to enable non-invasive analysis of intra-tumor heterogeneity.In this study, we planned to construct a prediction study of preoperative lymph node metastasis and prognosis of pancreatic cancer based on multimodal imaging, so as to provide a basis for clinical treatment decision and prognosis.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- radical resection was performed, and histopathologically confirmed pancreatic ductal adenocarcinoma and lymph node status;2) CT and/or MRI enhancement examinations were performed 2 weeks before surgery;3) Patients with complete clinical data
Exclusion criteria
- (1)Patients who received radiotherapy or chemotherapy before preoperative imaging examination;2) Poor image quality.
Treatment and study plan
Primary outcomes
-
radiomics features
Time frame: After sketching the ROI
1409 radiomics features can be extracted from the images.
Sponsors and collaborators
Lead sponsor
Peking University Third Hospital
Other
Registry information
Important dates
- Study start
- 2010
- Primary completion
- 2020
- Study completion
- 2020
- First posted
- Jul 8, 2021
- Registry last updated
- Jul 8, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
NCT03410030
Digestive System Diseases, Digestive System Neoplasms
Scottsdale, Arizona, United States
View Trial DetailsDistal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)
NCT04483726
Adenocarcinoma, Carcinoma
Clichy, France
View Trial DetailsA Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
NCT05867121
Bronchial Neoplasms, Carcinoma
Los Angeles, California, United States
View Trial DetailsStudy Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
NCT05546853
Pancreatic Ductal Adenocarcinoma
Grenoble, Alpes, France
View Trial Details